INS and type 2 diabetes mellitus: It stands to reason that the accumulation of pro-inflammatory leukocytes and elevation of the concentration of their pro-inflammatory soluble mediators inside insulin-sensitive tissues is a high-priority target of therapy aimed to restore normal insulin-sensitivity in T2D as well as prevent any T2D-associated liver impairment that can be a consequence of, or drive hepatic IR.